Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.

Item
http://www.wikidata.org/entity/Q39732691
Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot studyTwo studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Treatment decisions in multiple sclerosis - insights from real-world observational studies.Natalizumab treatment of multiple sclerosis: new insights.Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.Therapy of highly active pediatric multiple sclerosis.Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab fingolimod efficacy in multiple sclerosis
P2860

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.

Item
http://www.wikidata.org/entity/Q39732691
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Natalizumab versus fingolimod ...... rst-line injectable therapies.
@en
Natalizumab versus fingolimod ...... rst-line injectable therapies.
@nl
type
label
Natalizumab versus fingolimod ...... rst-line injectable therapies.
@en
Natalizumab versus fingolimod ...... rst-line injectable therapies.
@nl
prefLabel
Natalizumab versus fingolimod ...... rst-line injectable therapies.
@en
Natalizumab versus fingolimod ...... rst-line injectable therapies.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Natalizumab versus fingolimod ...... rst-line injectable therapies.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921